new
   Indications for Rasagiline (Azilect)
508
Nov 13, 2025

Rasagiline (Azilect) is a selective and irreversible monoamine oxidase type B (MAO-B) inhibitor. Since its approval by the U.S. FDA in 2006, it has become an important treatment option for Parkinson's disease. Its precise indication positioning, standardized dosage form design, and standardized storage requirements constitute the core elements of clinical medication use.

Indications for Rasagiline (Azilect)

Core Therapeutic Area

Rasagiline is clearly indicated for the treatment of Parkinson's disease (PD), covering disease management across different stages from early to advanced.

The medication can be used as monotherapy or a key component of combination therapy regimens.

Clinical Application Scenarios

Monotherapy: For patients with early-stage Parkinson's disease who have not received levodopa treatment.

Combination therapy: Used as an adjunct to levodopa to improve motor fluctuation symptoms.

Special populations: Can be used in combination with other anti-Parkinsonian medications such as dopamine agonists.

Specifications and Properties of Rasagiline (Azilect)

0.5 mg Tablets

White to off-white, round, flat tablets with beveled edges. One side is imprinted with "GIL 0.5", and the other side is a smooth surface.

1 mg Tablets

White to off-white, round, flat tablets with beveled edges. One side is imprinted with "GIL 1", and the other side remains smooth.

Both dosage forms use the same excipient formula: mannitol, starch, pregelatinized starch, colloidal silicon dioxide, stearic acid, and talc, ensuring drug stability and bioavailability.

Storage Methods for Rasagiline (Azilect)

Temperature Control Standards

The medication should be stored at 25°C (77°F), with short-term fluctuations allowed within the range of 15°C to 30°C (59°F to 86°F).

Packaging and Environmental Requirements

Packaging specifications: Supplied in bottles containing 30 tablets.

Environmental protection: Avoid exposure to direct sunlight, humid environments, and contact with heat sources.

Safety Precautions

Immediately seal the bottle cap after each use.

Store in a safe location out of the reach of children.

Avoid storing together with strong oxidants, acids, or alkalis.

Note: For internal discussion among medical personnel only. For specific medication, please consult the attending physician. Drug information may change over time. For the latest information, we recommend adding a medical consultant or consulting for free online.
RELATED ARTICLES
Contraindications and Special Populations of Brensocatib Tablets

The prescribing information for Brixocatib tablets indicates that there are no absolute contraindications, but...

Friday, August 7th, 2026, 17:16
Dosage and Administration of Isatuximab Injection (Sarclisa)

Sarclisa must be administered under the supervision of a healthcare professional, and the administration site must...

Friday, August 7th, 2026, 14:56
Indications and Dosage of Tepotinib

Tepotinib is an oral MET tyrosine kinase inhibitor indicated for the treatment of non-small cell lung cancer...

Thursday, August 6th, 2026, 15:43
Dosage and Administration of Zidesamtinib

Before the first administration of Ziditnib, the following baseline assessments must be completed:...

Thursday, August 6th, 2026, 15:41
RELATED MEDICATIONS
Contact Medical Consultant
Global Drug Search
Clinical recruitment
overseas medical treatment
Remote consultation
Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.
Click to submit medical consultant
Contact Us
haiousales@gmail.com
Welcome To Consult
Seagull Pharmacy.,Ltd All rights reserved